---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-008511"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:28:06.152687+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences realigns to accelerate AFib catheter program after strong clinical data

## Summary
- 100% acute success at 6 months (75/75 patients); 96% durable PVI at 12 months (45/47).
- Reducing headcount in sales/marketing; redirecting resources to cardiac catheter program and pivotal IDE study.
- Streamlining soft-tissue ablation to focus on benign thyroid nodules and real-world data.
- Late-breaking 12-month follow-up data to be presented at Heart Rhythm 2026 on April 25.

## SEC filing metadata
- accession: 0001437749-26-008511
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926008511/0001437749-26-008511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926008511/plse20260316c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-008511
- JSON: https://secwatch.observer/filing/0001437749-26-008511.json
- Plain text: https://secwatch.observer/filing/0001437749-26-008511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.